NYSE:RVTYLife Sciences
Why Revvity (RVTY) Is Up 6.4% After New Lilly AI Drug Discovery Partnership Integration
On 9 January 2026, Revvity, Inc. announced a collaboration with Eli Lilly to integrate Lilly’s TuneLab AI/ML predictive drug discovery models into the Revvity Signals platform via the Signals Xynthetica Models-as-a-Service framework, enabling federated learning while keeping participants’ proprietary data private.
An interesting aspect is that Lilly and Revvity will jointly fund access to Signals One, Signals Xynthetica, and modeling credits, potentially widening AI adoption among smaller...